Group 1 - Kangchen Pharmaceutical and Puris reached the daily limit increase, while Duri Pharmaceutical rose over 10% [1] - Huahai Pharmaceutical, Haoyuan Pharmaceutical, Jimin Health, Warner Pharmaceuticals, and Medisyn also experienced gains [1]

Profit Distribution Plan - The company plans to distribute a cash dividend of 0.80 RMB per 10 shares (including tax) to all shareholders, based on a total share capital of 212,098,765 shares as of August 27, 2025, resulting in a total cash dividend of approximately 151,761,472.63 RMB, which represents 11.18% of the undistributed profits as of June 30, 2025 [1][2][3] Legal and Compliance - The profit distribution plan has been approved in previous board meetings and complies with relevant laws and regulations, including the Company Law of the People's Republic of China and the guidelines for cash dividends for listed companies [2][3] Decision-Making Process - The company’s board of directors has the authority to decide on the profit distribution plan without needing to submit it to the shareholders' meeting, as it falls within the decision-making powers granted by the shareholders [3]

Core Viewpoint - The company has announced adjustments to the implementation location and timeline of its convertible bond fundraising project, specifically the CDMO project, extending the expected completion date to June 2029 [2][4][9]. Fundraising Overview - The company plans to issue convertible bonds totaling 822.35 million yuan, with a net amount of approximately 811.74 million yuan after deducting issuance costs [2][3]. - The funds will be allocated to the high-end pharmaceutical intermediates and active pharmaceutical ingredients CDMO industrialization project, with a total investment of 863.51 million yuan, of which 811.74 million yuan is expected to be funded from the raised capital [3][4]. Project Adjustment Details - The implementation location for certain workshops and auxiliary facilities of the CDMO project will be adjusted within the original factory area, and the project timeline has been extended to June 2029 [2][4][6]. - The adjustments are made to optimize space utilization and reduce construction and operational costs while complying with government requirements [6][9]. Reasons for Delay - The project was initially scheduled for completion between June 2024 and June 2026, but delays occurred due to funding constraints and the need for additional government approvals, which are expected to take 4-6 months [6][7]. - Market conditions have changed, leading to a decrease in demand for CDMO services, prompting the company to reassess the project timeline and prioritize certain facilities [7][8]. Impact of Adjustments - The adjustments will not change the total investment amount, project scale, or the use of raised funds, and are deemed necessary for the project's successful implementation [9][10]. - The company has followed the required approval processes for these adjustments, ensuring compliance with relevant regulations [9][10].

Core Viewpoint - Shanghai Haoyuan Chemexpress Co., Ltd. reported significant growth in revenue and net profit for the first half of 2025, driven by strong performance in its high-margin life science reagent business and effective cost management [1][5]. Financial Performance - Revenue for the first half of 2025 reached approximately 1.31 billion RMB, representing a 24.20% increase compared to the same period last year [5]. - Total profit increased by 130.95% to approximately 181.62 million RMB, while net profit attributable to shareholders rose by 115.55% to approximately 151.76 million RMB [5]. - The company's net assets at the end of the reporting period were approximately 3.02 billion RMB, a 5.05% increase from the end of the previous year [5]. Business Overview - The company focuses on providing professional and efficient small molecule, large molecule, and new molecular type drugs, with a comprehensive service platform covering drug research and production [6][7]. - Key business segments include life science reagents, raw materials, intermediates, and formulation development, with a strong emphasis on innovation and high-value products [6][7]. - The life science reagent business is positioned as a leader in the domestic market, particularly in the area of tool compounds, which are essential for drug discovery [7][8]. Industry Context - The global pharmaceutical R&D expenditure is projected to grow by 1.7% in 2024, reaching approximately 289 billion USD, with the life science reagent market expected to reach 66.82 billion USD by 2026, growing at a compound annual growth rate (CAGR) of 7.9% from 2020 to 2026 [8][10]. - The Chinese life science reagent market has seen significant growth, increasing from approximately 25 billion RMB in 2018 to about 48 billion RMB in 2022, with a CAGR of around 18% [8]. - The market for molecular building blocks is anticipated to reach 54.6 billion USD by 2026, indicating a robust growth trajectory [9].

Core Viewpoint - Shanghai Haoyuan Pharmaceutical Co., Ltd. plans to distribute a cash dividend of 0.80 yuan per 10 shares, totaling approximately 16.97 million yuan, which represents 11.18% of the net profit attributable to shareholders for the first half of 2025 [1][2]. Financial Performance - Total assets increased by 6.13% to approximately 5.84 billion yuan compared to the end of the previous year [2]. - Operating revenue for the reporting period was approximately 1.31 billion yuan, reflecting a 24.20% increase from approximately 1.06 billion yuan in the same period last year [3]. - Total profit rose significantly by 130.95% to approximately 181.62 million yuan compared to approximately 78.64 million yuan in the previous year [3]. - Net profit attributable to shareholders, after deducting non-recurring gains and losses, was approximately 140.57 million yuan, up 111.40% from approximately 66.50 million yuan in the same period last year [3]. - Basic and diluted earnings per share were both 0.72 yuan, representing an increase of 118.18% from 0.33 yuan in the previous year [3]. Shareholder Information - As of the end of the reporting period, the total number of shareholders was 10,882 [3]. - The top ten shareholders included various entities, with the largest shareholder holding 3.96% of the shares [4].

Core Viewpoint - The company, Shanghai Haoyuan Pharmaceutical Co., Ltd., is adjusting the implementation locations and delaying the timeline for its convertible bond fundraising project, specifically for the CDMO project, while ensuring that the total investment amount and production capacity remain unchanged [1][6]. Fundraising Overview - The company has received approval from the China Securities Regulatory Commission to issue convertible bonds totaling RMB 822.35 million, with a maturity of 6 years and a face value of RMB 100 per bond [1][2]. - The funds will be stored in a dedicated account, and the company has signed a tripartite/four-party supervision agreement with the sponsor and the bank [1]. Investment Project Details - The total investment for the high-end pharmaceutical intermediates and raw materials CDMO industrialization project (Phase I) is RMB 863.51 million, with RMB 811.74 million planned to be funded from the raised capital [2][3]. Adjustments and Delays - The project site is located in the chemical park in Chengwu County, Heze City, Shandong Province, covering approximately 158 acres [3][4]. - Adjustments include relocating certain workshops and auxiliary facilities to optimize space and reduce costs, without affecting the total investment or production capacity [4][6]. - The project timeline has been extended to June 2029 due to delays in funding and the need for additional government approvals [5][6]. Impact of Adjustments - The adjustments are based on practical project implementation conditions and do not alter the investment content or total amount, ensuring no significant adverse effects on the company's operations [6][7]. - The company has followed necessary approval procedures for these adjustments, complying with relevant regulations [6][7].

Group 1 - The company will hold a semi-annual performance and cash dividend presentation on September 26, 2025, from 13:00 to 14:30 [1][2] - The presentation will be conducted via video live streaming and online interaction, allowing investors to engage with the company [2][3] - Key personnel attending the presentation include the Chairman, General Manager, Secretary of the Board, Chief Financial Officer, Head of Internal Audit, and an Independent Director [2] Group 2 - Investors can submit questions for the presentation from September 19 to September 25, 2025, through the designated website or company email [1][3] - The company will address commonly asked questions during the presentation, ensuring transparency and engagement with investors [2][3] - After the presentation, investors can access the main content and details of the event on the Shanghai Stock Exchange Roadshow Center website [3]

Summary of Key Points Core Viewpoint The report outlines the fundraising activities and the utilization of funds by Shanghai Haoyuan Pharmaceutical Co., Ltd. for the first half of 2025, detailing the amount raised, the allocation of funds, and the management of these funds. Group 1: Fundraising Overview - The company raised a total of RMB 822.35 million through the issuance of convertible bonds, with a maturity of 6 years and a face value of RMB 100 per bond [1][2]. - As of June 30, 2025, the balance in the fundraising account was RMB 420,589,058.15, which includes interest income after deducting fees [1][2]. Group 2: Fund Utilization - The net amount of funds raised was RMB 811,737,609.85, with RMB 311,050,738.57 allocated to investment projects and RMB 86 million used for cash management [1][2]. - The company has not used any idle funds for temporary working capital during the reporting period [2][3]. Group 3: Fund Management - The company established a dedicated account for the management of raised funds, ensuring compliance with regulations and maintaining transparency [1][2]. - A three-party supervision agreement was signed with banks and the sponsor to oversee the management of the funds [1][2]. Group 4: Project Updates - The company has approved the use of raised funds to replace pre-invested self-raised funds amounting to RMB 40,333,017.97 for specific projects [2][3]. - The timeline for certain projects has been extended, with the "High-end Pharmaceutical Intermediates and Raw Materials CDMO Industrialization Project" expected to reach operational status by June 2029 [3][4]. Group 5: Compliance and Reporting - The company has adhered to the regulatory requirements for fundraising and has accurately disclosed the status of fund utilization [3][4]. - No violations in the management of raised funds have been reported, and all disclosures have been made in a timely and accurate manner [3][4].

Core Viewpoint - Shanghai Haoyuan Chemexpress Co., Ltd. has implemented a "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan, focusing on enhancing operational efficiency and market competitiveness while ensuring shareholder returns through strategic initiatives and financial performance improvements [1][2]. Group 1: Business Focus and Strategy - The company is transitioning from a "business investment phase" to a "strategic harvest phase," accelerating its globalization process and expanding overseas revenue, which reached 560 million yuan, a year-on-year increase of 24.20% [2][3]. - The company has established an integrated service platform covering the entire pharmaceutical development lifecycle, from starting materials to intermediates, APIs, and formulations, enhancing its ability to support drug development [6][11]. - The company emphasizes high-value custom synthesis services in its life sciences reagent business, leveraging technical advantages to build differentiated competitive barriers in niche markets [3][11]. Group 2: Financial Performance - In the first half of 2025, the company achieved operating revenue of 1.311 billion yuan, a year-on-year increase of 24.20%, and a net profit attributable to shareholders of 152 million yuan, up 115.55% [2][3]. - The company reported an EBITDA of 260 million yuan, reflecting a 39.67% increase compared to the previous year [2]. Group 3: Research and Development - The company maintains a strong focus on R&D, with a research expense ratio exceeding 10% over the past three years, and has applied for a total of 426 patents, with 197 currently valid [11][12]. - The company is committed to integrating green chemistry principles into its drug development and production processes, enhancing efficiency and reducing costs through innovative technologies [12][22]. Group 4: Governance and Compliance - The company has streamlined its governance structure by reducing the board from nine to seven members, enhancing the professionalism and strategic alignment of its governance [14][15]. - The company has implemented a comprehensive upgrade of its governance systems to comply with new regulations, ensuring effective risk management and operational efficiency [16][17]. Group 5: Shareholder Returns and ESG Commitment - The company adheres to a dual-frequency dividend mechanism, optimizing shareholder returns in line with its three-year dividend plan, with cash dividends increasing compared to the previous year [19][21]. - The company actively promotes ESG principles, establishing a three-tier ESG management framework and releasing its second ESG report, showcasing its commitment to sustainable development [22].

Group 1 - The company announced a change in registered capital and amendments to its Articles of Association, which will be submitted for shareholder approval [1][4] - As of August 27, 2025, the company’s registered capital increased by 10,479.00 CNY due to the conversion of "Haoyuan Convertible Bonds" into 10,479 shares [1] - The company completed the registration procedures for the first vesting period of the 2022 restricted stock incentive plan, resulting in an increase of 648,570 shares and registered capital by 648,570.00 CNY [2] - The company reduced its total share capital by 47,725 shares and registered capital by 47,725.00 CNY due to the cancellation of compensation shares related to performance commitments [3] - The company completed the registration for the second vesting period of the 2023 restricted stock incentive plan, increasing total share capital by 527,660 shares and registered capital by 527,660.00 CNY [4] - The total share capital changed from 210,959,781 shares to 212,098,765 shares, and registered capital changed from 210,959,781.00 CNY to 212,098,765.00 CNY [4] Group 2 - The company plans to amend its Articles of Association to reflect changes in registered capital and total share capital, in accordance with relevant laws and regulations [4] - The specific amendments to the Articles of Association include updates to the registered capital and total share capital clauses [4]